GDF-15 Levels in Risk Stratification in Acute Pulmonary Embolism
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pulmonary Embolism
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Prospective observational study evaluating serum GDF-15 levels in patients with acute pulmonary embolism (APE). In APE right ventricle failure developing due to ischemia and myocarditis is considered the primary cause of death, however, its pathomechanism has not been fully established yet. Growth d...
Prospective observational study evaluating serum GDF-15 levels in patients with acute pulmonary embolism (APE). In APE right ventricle failure developing due to ischemia and myocarditis is considered the primary cause of death, however, its pathomechanism has not been fully established yet. Growth differentiation factor 15 (GDF-15) is a chemokine secreted by activated macrophages in response to oxidative stress. It has now been shown that ischemic injury, mechanical stretch, and pro-inflammatory cytokines also stimulate the expression of GDF-15 in cardiac myocytes. The objective of this project is to describe the role of GDF-15 in the pathomechanism of acute right ventricle failure in the setting of acute pulmonary embolism and to verify the hypothesis that higher serum concentrations of GDF-15 are associated with more advanced right ventricle dysfunction and failure.
Tracking Information
- NCT #
- NCT03672123
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Marta Z Skowronska, MD Medical University of Warsaw Study Director: Piotr Pruszczyk, Prof. Medical University of Warsaw
Get Well Soon